Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.

Neuro-oncology - 14 Feb 2019

Yamashita Alex Shimura, da Costa Rosa Marina, Borodovsky Alexandra, Festuccia William T, Chan Timothy, Riggins Gregory J

Abstract excerpt

BACKGROUND: Isocitrate deyhydrogenase (IDH) mutant glioma comprises the majority of grades II-III gliomas and nearly all secondary glioblastomas. These progressive gliomas arise from mutations in IDH1 or IDH2 that pathologically produce D-2-hydroxyglutarate (2HG), which interferes with cell reactions using alpha ketoglutarate, leading to a hypermethylated genome and epigenetic dysregulation of gene expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Azacitidine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenesis, Genetic

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mice, Nude

Share to Temozolomide

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 30184215
DOI: 10.1093/neuonc/noy146
PMCID: PMC6374765

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.PMID 30184215Read ↗

5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.Semantic proximity Read ↗

Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas.Semantic proximity Read ↗

EZH2 inhibition sensitizes IDH1R132H mutant gliomas to histone deacetylase inhibitorSemantic proximity Read ↗

HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma.Semantic proximity Read ↗

HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant gliomaSemantic proximity Read ↗

IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.Semantic proximity Read ↗

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.Semantic proximity Read ↗

Oncometabolite 2-hydroxyglutarate suppresses basal protein levels of DNA polymerase beta that enhances alkylating agent and PARG inhibition induced cytotoxicity.Semantic proximity Read ↗

Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.Semantic proximity Read ↗

Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.